Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study

Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study

Background. sequential chemotherapy can maintain dose intensity and preclude cumulative toxicity by increasing drug diversity. Purpose. to investigate the toxicity and efficacy of the sequential regimen of gemcitabine followed by paclitaxel in first line advanced stage non-sma...

Full description

Bibliographic Details
Main Authors: V. Surmont, J. G. J. V. Aerts, K. Y. Tan, F. Schramel, R. Vernhout, H. C. Hoogsteden, R. J. van Klaveren
Format: Article
Language:English
Published: Hindawi Limited 2009-01-01
Series:Journal of Oncology
Online Access:http://dx.doi.org/10.1155/2009/457418

Internet

http://dx.doi.org/10.1155/2009/457418

Similar Items